COVID-19 Vaccine Information and Updates
Read the Latest
Children's Hospital is part of the UPMC family.
Be safe anytime, anywhere.
To find a pediatrician or pediatric specialist, please call 412-692-7337 or search our directory.
A resource for our network of referring physicians.
For more information about research, please call our main office at 412-692-6438.
Ranked #9 Nationally by U.S. News & World Report.
The clinical mission of the Division of Blood and Marrow Transplantation and Cellular Therapies is to design and test disease-specific and biologically rational novel reduced-toxicity transplantation regimens for patients with high-risk leukemia or lymphoma, and for those afflicted with life-threatening inherited conditions that can lead to bone marrow failure, immune deficiency, autoimmune diseases, and neurodegenerative conditions including but not limited to leukodystrophies and mucopolysaccharidosis syndromes.
Our translational research mission focuses on developing new cellular immune therapy programs for cancer and viral infections and testing the use of bone marrow transplantation following solid organ transplant to establish immunity, tolerance, and extend organ survival.
We’re committed to nurturing the next generation of pediatric specialists.
Children’s is at the forefront of medical research and innovation.
Schedule an appointment or consultation with us at 412-692-6740.
UPMC Children’s Hospital of Pittsburgh is one of a small group of children's hospitals that offers CAR (chimeric antigen receptor) T-cell therapy, a type of immunotherapy that uses a person’s own genetically modified T cells to find and kill cancer cells. At UPMC Children’s Hospital we use KYMRIAH®, an FDA-approved CAR T-cell therapy for children and young adults with relapsed or refracted B-cell acute lymphoblastic leukemia (ALL).
Blood and marrow transplantation (BMT) is used successfully to treat a number of cancers, blood diseases, and immune disorders that were once considered incurable. Our proactive patient care with close monitoring of the immune system has resulted in unsurpassed outcomes since 2010. Our one-year transplant-related mortality is below 10 percent for all allogeneic marrow, PBSC, and cord blood transplants and ~5 percent for our institutional reduced-intensity allogeneic transplant trial.
The division has a strong programmatic focus on reduced-intensity/toxicity cord blood, bone marrow, and stem cell transplantation for inherited disorders. In 2008, Dr. Szabolcs designed the first ever reduced intensity cord blood transplantation trial for inborn errors of metabolism with similar engraftment rates as ablative therapies, Biol Blood Marrow Transplant. 2014 Mar;20(3):326.
Our current, further refined Pitt trial is leading in safety and efficacy saving children/young adults from not only toxic deaths but also from brain, lung, liver, heart, GU, and other organ toxicities. The absence of severe, or extensive GVHD and improved quality of life permits early return to their local communities while our integrated Ronald McDonald House offers comfortable housing during the weeks away from home.
As an evidence of our programmatic efforts to make transplant safer and more effective, we are conducting a prospective trial for children and young adults afflicted with high-risk acute myeloid leukemia (AML) – “Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS.”
The division has a clinical research focus on Crohn’s disease and other autoimmune disorders. Novel, reduced toxicity/intensity protocols are opening for advanced leukemia, sickle cell disease, and thalassemia.
In collaboration with other University of Pittsburgh investigators, we are the only center in the world to offer tandem lung and bone marrow transplantation for pediatric and adult patients with immunodeficiencies who have progressed to pulmonary failure. Ongoing collaborations at Pitt will pioneer further applications.
Banner Care For Our Bonus Baby
Children's blog post (9/29/14)
Teen Improving After Transplant At Children’s Hospital
CBS Pittsburgh (12/18/13)
'Yo Gabba Gabba!' trip planned for Braddock girl who calls Children's Hospital home
Pittsburgh Post-Gazette (8/29/13)
Study of Myeloablative and Reduced-Intensity Conditioning Regimens for Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Protocols for a Research Database and Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-versus-host Disease in Children and Young Adults with Blood Cancers Undergoing Donor Stem Cell Transplant
Study of Letermovir in Pediatric Participants from Birth to Less than 18 Years of Age at Risk of Developing CMV Infection and/or Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Autologous Stem Cell Transplantation with CD34 Selected Peripheral Blood Stem Cells (PBSC) in Pediatric and Young Adult Patients with Severe Crohn's Disease
Bilateral Orthotopic Lung Transplant (BOLT) in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant (BMT) From Partially HLA-Matched Cadaveric Donors
Study of Reduced-Intensity Conditioning In Patients With Non-Malignant Disorders Undergoing Umbilical Cord, Bone Marrow, or Peripheral Blood Stem Cell Transplantation
Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
Long-term Follow-up Registry and Biorepository for Patients Diagnosed With Primary Immunodeficiencies, Malignancy, and/or Eligible to Undergo Hematopoietic Stem Cell Transplant
Hematopoietic Graft Engineering: Pre-clinical Studies of Immunocompetence
Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients with Suspected Lower Respiratory Tract Infection
A Prospective Natural History Study of Diagnosis, Treatment, and Outcomes of Children with SCID Disorders
T-Cell Depleted, Alternative Donor Transplant in Pediatric and Young Adult Patients with Severe Sickle Cell Disease
Use of Miltenyi Biotec’s CliniMACS CD34 Reagent System as a Humanitarian Use Device for Isolation of Hematopoietic Stem Cells or T-cell Depletion in Multiple Settings
Autologous Stem Cell Transplantation with CD34-Selected Peripheral Blood Stem Cells in Patients with Treatment-Resistant Systemic Sclerosis
Lung Transplant in Tandem with Bone Marrow Transplant for Combined Lung and Bone Marrow Failure
Children's Hospital's main campus is located in the Lawrenceville neighborhood. Our main hospital address is:
UPMC Children’s Hospital of Pittsburgh
One Children’s Hospital Way
4401 Penn Ave.
Pittsburgh, PA 15224
In addition to the main hospital, Children's has many convenient locations in other neighborhoods throughout the greater Pittsburgh region.
With myCHP, you can request appointments, review test results, and more.
For questions about a hospital bill call:
To pay your bill online, please visit UPMC's online bill payment system.
Interested in giving to Children's Hospital? Support the hospital by making a donation online, joining our Heroes in Healing monthly donor program, or visiting our site to learn about the other ways you can give back.